Vanguard Group
VTGN icon

Vanguard Group’s VistaGen Therapeutics VTGN Stock Holding History

Vanguard Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.21M Buy
1,824,738
+137,003
+8% +$495K ﹤0.01% 3720
2025
Q3 		$5.99M Sell
1,687,735
-71,907
-4% -$215K ﹤0.01% 3212
2025
Q2 		$3.52M Sell
1,759,642
-200,530
-10% -$456K ﹤0.01% 3323
2025
Q1 		$4.9M Sell
1,960,172
-60,179
-3% -$170K ﹤0.01% 3179
2024
Q4 		$5.96M Buy
2,020,351
+227,185
+13% +$639K ﹤0.01% 3199
2024
Q3 		$5.4M Hold
1,793,166
– – ﹤0.01% 3244
2024
Q2 		$6.24M Hold
1,793,166
– – ﹤0.01% 3159
2024
Q1 		$9.47M Sell
1,793,166
-41,346
-2% -$199K ﹤0.01% 2985
2023
Q4 		$9.43M Buy
1,834,512
+1,580,797
+623% +$5.98M ﹤0.01% 2978
2023
Q3 		$1.33M Buy
253,715
+29,804
+13% +$132K ﹤0.01% 3735
2023
Q2 		$419K Buy
223,911
+59,170
+36% +$207K ﹤0.01% 4167
2023
Q1 		$616K Buy
164,741
+6,940
+4% +$36.4K ﹤0.01% 4063
2022
Q4 		$488K Sell
157,801
-53
-0% -$199 ﹤0.01% 4106
2022
Q3 		$720K Sell
157,854
-174,384
-52% -$1.73M ﹤0.01% 4100
2022
Q2 		$8.77M Buy
332,238
+23,302
+8% +$823K ﹤0.01% 3065
2022
Q1 		$11.5M Buy
308,936
+118
+0% +$5.14K ﹤0.01% 3076
2021
Q4 		$18.1M Buy
308,818
+15,911
+5% +$1.04M ﹤0.01% 2899
2021
Q3 		$24.1M Sell
292,907
-3,191
-1% -$277K ﹤0.01% 2754
2021
Q2 		$28M Buy
296,098
+102,617
+53% +$7.6M ﹤0.01% 2668
2021
Q1 		$12.4M Buy
193,481
+84,793
+78% +$5.66M ﹤0.01% 3035
2020
Q4 		$6.33M Buy
108,688
+43,852
+68% +$1.12M ﹤0.01% 3243
2020
Q3 		$1.36M Buy
64,836
+25,992
+67% +$538K ﹤0.01% 3594
2020
Q2 		$615K Sell
38,844
-1,389
-3% -$19K ﹤0.01% 3721
2020
Q1 		$531K Buy
40,233
+80
+0.2% +$1.47K ﹤0.01% 3661
2019
Q4 		$831K Hold
40,153
– – ﹤0.01% 3679
2019
Q3 		$1.29M Buy
40,153
+280
+0.7% +$6.24K ﹤0.01% 3573
2019
Q2 		$868K Buy
39,873
+1,191
+3% +$31.6K ﹤0.01% 3714
2019
Q1 		$1.49M Buy
38,682
+12,952
+50% +$565K ﹤0.01% 3531
2018
Q4 		$1.16M Buy
25,730
+17,148
+200% +$934K ﹤0.01% 3522
2018
Q3 		$373K Buy
8,582
+2,569
+43% +$104K ﹤0.01% 3899
2018
Q2 		$247K Buy
6,013
+175
+3% +$6.08K ﹤0.01% 3947
2018
Q1 		$163K Buy
+5,838
New +$217K ﹤0.01% 3982
2017
Q4 		– Sell
-1,358
Closed -$65K – 4078
2017
Q3 		$65K Buy
1,358
+124
+10% +$6.53K ﹤0.01% 4016
2017
Q2 		$69K Sell
1,234
-71
-5% -$4.16K ﹤0.01% 4008
2017
Q1 		$77K Buy
1,305
+50
+4% +$4.05K ﹤0.01% 4001
2016
Q4 		$140K Buy
+1,255
New +$146K ﹤0.01% 3941

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group's VTGN Position: Q4 2025 in Review

Vanguard Group increased its VistaGen Therapeutics (VTGN) stake by 8.1% in Q4 2025, buying an estimated $495K and bringing the position to 1,824,738 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3720.

Vanguard Group first reported a position in VTGN in Q4 2016 and has held it in 36 quarters since. The position peaked at $28M in Q2 2021. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Vanguard Group held 1,824,738 shares of VistaGen Therapeutics worth $1.21M as of Q4 2025.
  • Vanguard Group bought 137,003 VistaGen Therapeutics shares in Q4 2025, an estimated $495K.
  • VistaGen Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3720 holding.
  • Vanguard Group first reported a position in VistaGen Therapeutics in Q4 2016 and has held it in 36 quarters since.
  • Vanguard Group's VistaGen Therapeutics position peaked at $28M in Q2 2021.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.